Calcium D-Glucarate (hydrate)
(Synonyms: 葡萄糖二酸鈣) 目录号 : GC47020
The calcium salt form of D-glucaric acid
Cas No.:5793-89-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Calcium D-glucarate is the calcium salt form of D-glucaric acid.1 D-Glucaric acid is an end product of D-glucuronic acid metabolism in mammals that has also been found in fruits and vegetables and has anticancer activity.2 It is produced by the oxidation of D-glucuronic acid and is a precursor in the biosynthesis of the β-glucuronidase inhibitor D-glucaro-1,4-lactone in vivo.1 Dietary administration of calcium D-glucarate (10% w/w) reduces tumor growth in a rat model of mammary tumorigenesis induced by 7,12-dimethylbenz[a]anthracene (DMBA).3 Urinary D-glucaric acid levels have been used as a marker for xenobiotic-induced phase II metabolism in patients with rheumatoid arthritis or individuals exposed to environmental toxicants.4,5
1.Walaszek, Z.Potential use of D-glucaric acid derivatives in cancer preventionCancer Lett.54(1-2)(1990) 2.ZÓ?taszek, R., Hanausek, M., Kiliańska, Z., et al.The biological role of D-glucaric acid and its derivatives: potential use in medicinePostepy. Hig. Med. Dosw. (Online)62451-462(2008) 3.Walaszek, Z., Hanausek-Walaszek, M., Minton, J.P., et al.Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesisCarcinogenesis7(9)1463-1466(1986) 4.Addyman, R., Beyeler, C., Astbury, C., et al.Urinary glucaric acid excretion in rheumatoid arthritis: influence of disease activity and disease modifying drugsAnn. Rheum. Dis.55(7)478-481(1996) 5.IdÉo, G., Bellati, G., Bellohuono, A., et al.Urinary D-glucaric acid excretion in the Seveso area, polluted by tetrachloro-dibenzo-p-dioxin (TCDD): five years of experienceEnviron. Health Perspect.60151-157(1976)
| Cas No. | 5793-89-5 | SDF | |
| 别名 | 葡萄糖二酸鈣 | ||
| Canonical SMILES | [O-]C([C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O)=O.[Ca+2].O.O.O.O | ||
| 分子式 | C6H8O8.Ca [4H2O] | 分子量 | 320.3 |
| 溶解度 | Methanol: slightly soluble,PBS (pH 7.2): slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1221 mL | 15.6104 mL | 31.2207 mL |
| 5 mM | 0.6244 mL | 3.1221 mL | 6.2441 mL |
| 10 mM | 0.3122 mL | 1.561 mL | 3.1221 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet